Diego Lugo Baruqui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diego Lugo Baruqui has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Mendel Shloush
Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
2 shared publications - Vania Rodriguez
Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA
2 shared publications - Victor Guillen
Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA
2 shared publications - Adam Jacobs
Mount Sinai Medical Center, Miami Beach, FL, United States
1 shared publication - Ahmed Aly Elghawy
Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, OH, United States
1 shared publication - Ben Johns
Ultrafast Nanoscience Group, Department of Physics, Umeå University, 90187, Umeå, Sweden
1 shared publication
Latest Publications
- Open Access
- 7 April 2026
- Vol. 70 (3) , e260028
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.
Tirzepatide,a dual GLP-1 and GIP receptor agonist, is increasingly used for weight management in both patients with diabetes and patients without diabetes. While gastrointestinal side effects such as nausea are common, severe metabolic complications like ketoacidosis are rare and often overlooked. We report the case of a 38-year-old woman with congenital heart disease who developed acute ketoacidosis with hyperglycemia following five months of tirzepatide therapy. Laboratory findings confirmed high anion gap metabolic acidosis, elevated ketones, and significant hyperglycemia. With supportive care, including intravenous fluids, insulin infusion, and electrolyte replacement, she recovered fully. This represents a rare case of tirzepatide-induced hyperglycemic ketoacidosis in a patient without diabetes. In contrast, the two previously reported cases by Singh and cols. and Iqbal and cols. involved patients without diabetes who developed euglycemic ketoacidosis with normal glucose levels while on tirzepatide. This case underscores the importance of vigilant monitoring for metabolic complications, including hyperglycemia and ketoacidosis, in patients without diabetes, particularly those with comorbidities.
- 7 April 2026
- Vol. 70 (3) , e260028
Open AccessTirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.
Tirzepatide,a dual GLP-1 and GIP receptor agonist, is increasingly used for weight management in both patients with diabetes and patients without diabetes. While gastrointestinal side effects such as nausea are common, severe metabolic complications like ketoacidosis are rare and often overlooked. We report the case of a 38-year-old woman with congenital heart disease who developed acute ketoacidosis with hyperglycemia following five months of tirzepatide therapy. Laboratory findings confirmed high anion gap metabolic acidosis, elevated ketones, and significant hyperglycemia. With supportive care, including intravenous fluids, insulin infusion, and electrolyte replacement, she recovered fully. This represents a rare case of tirzepatide-induced hyperglycemic ketoacidosis in a patient without diabetes. In contrast, the two previously reported cases by Singh and cols. and Iqbal and cols. involved patients without diabetes who developed euglycemic ketoacidosis with normal glucose levels while on tirzepatide. This case underscores the importance of vigilant monitoring for metabolic complications, including hyperglycemia and ketoacidosis, in patients without diabetes, particularly those with comorbidities.
- Open Access
- 3 August 2023
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 19 (4) , 400-407
Current State of Platelet-rich Plasma in the Treatment of Rheumatic Disease: A Retrospective Review of the Literature
Introduction: Rheumatic diseases are a spectrum of autoimmune or inflammatory diseases that cause damage to the musculoskeletal system as well as vital organs, such as the heart, lungs, kidneys, and central nervous system. Methods: The study of rheumatic disease has made great pro-gress in the understanding and management of these conditions in the last few decades using dis-ease-modifying antirheumatic drugs and synthesized biological immunomodulating therapies. How-ever, one potential treatment that has not been well investigated in rheumatic disease is platelet-rich plasma (PRP). PRP is proposed to facilitate the healing of injured tendons and ligaments through a variety of mechanisms, including mitogenesis, angiogenesis and macrophage activation via cyto-kine release, although its exact mechanism is unclear. Result:: There has been a great deal of work in determining the exact preparation method and composition of PRP for regenerative purposes in or-thopedic surgery, sports medicine, dentistry, cardiac surgery, pediatric surgery, gynecology, urolo-gy, plastic surgery, ophthalmology, and dermatology. Despite this, there is a paucity of research on the impact of PRP on rheumatic disease Conclusion:: This study aims to summarize and evaluate the current research concerning the use of PRP in rheumatic disease.
- 3 August 2023
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 19 (4) , 400-407
Open AccessCurrent State of Platelet-rich Plasma in the Treatment of Rheumatic Disease: A Retrospective Review of the Literature
Introduction: Rheumatic diseases are a spectrum of autoimmune or inflammatory diseases that cause damage to the musculoskeletal system as well as vital organs, such as the heart, lungs, kidneys, and central nervous system. Methods: The study of rheumatic disease has made great pro-gress in the understanding and management of these conditions in the last few decades using dis-ease-modifying antirheumatic drugs and synthesized biological immunomodulating therapies. How-ever, one potential treatment that has not been well investigated in rheumatic disease is platelet-rich plasma (PRP). PRP is proposed to facilitate the healing of injured tendons and ligaments through a variety of mechanisms, including mitogenesis, angiogenesis and macrophage activation via cyto-kine release, although its exact mechanism is unclear. Result:: There has been a great deal of work in determining the exact preparation method and composition of PRP for regenerative purposes in or-thopedic surgery, sports medicine, dentistry, cardiac surgery, pediatric surgery, gynecology, urolo-gy, plastic surgery, ophthalmology, and dermatology. Despite this, there is a paucity of research on the impact of PRP on rheumatic disease Conclusion:: This study aims to summarize and evaluate the current research concerning the use of PRP in rheumatic disease.
- 1 January 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (3) , 1-4
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes
- 1 January 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (3) , 1-4
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Cardiovascular Imaging
- Vol. 29 (1) , 46-56
The Role of False Tendons in Left Ventricular Remodeling and Secondary Mitral Regurgitation After Acute Myocardial Infarction
Lo Presti S, et al. J Cardiovasc Imaging. 2020 Oct;29:e4. https://doi.org/10.4250/jcvi.2020.0112
- 1 January 2021
- Published by XMLink in Journal of Cardiovascular Imaging
- Vol. 29 (1) , 46-56
Open AccessThe Role of False Tendons in Left Ventricular Remodeling and Secondary Mitral Regurgitation After Acute Myocardial Infarction
Lo Presti S, et al. J Cardiovasc Imaging. 2020 Oct;29:e4. https://doi.org/10.4250/jcvi.2020.0112
- 21 February 2020
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 66 (7) , 739-745
Food and Drug Administration Malfunction Recalls of Left Ventricular Assist Devices
Left ventricular assist devices (LVADs) are being increasingly implanted given the increasing prevalence of patients with advanced heart failure stages. However, they are not exempt from device malfunctions. A PubMed search for the key words (left ventricular assist device malfunction) (ventricular assist system malfunction) was performed. We identified 28 publications in the US Food and Drug Administration (FDA) website database that addressed LVAD malfunction. Twenty-nine FDA recalls were identified regarding LVAD malfunctions: 17 regarding HeartWare ventricular assist device, six for HeartMate II, three for HeartMate 3, and three for total artificial heart. Mechanisms involved in LVAD malfunction include battery malfunction, loose driveline connector, malfunction of the system controller, loose power supply connector ports, malfunction of the driveline splice kit, problems with the percutaneous lead connection, disconnection of the bend relief and outflow graft and outflow graft occlusion among others. Multiple mechanisms could be linked to LVAD malfunction. However, multiple device modifications have been developed over the past decade to avoid recurrent malfunctions. Constant improvements and research in biotechnology are needed to prevent these complications. It remains to be seen if newer generation devices will lead to improved patient outcomes over the long term.
- 21 February 2020
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 66 (7) , 739-745
Food and Drug Administration Malfunction Recalls of Left Ventricular Assist Devices
Left ventricular assist devices (LVADs) are being increasingly implanted given the increasing prevalence of patients with advanced heart failure stages. However, they are not exempt from device malfunctions. A PubMed search for the key words (left ventricular assist device malfunction) (ventricular assist system malfunction) was performed. We identified 28 publications in the US Food and Drug Administration (FDA) website database that addressed LVAD malfunction. Twenty-nine FDA recalls were identified regarding LVAD malfunctions: 17 regarding HeartWare ventricular assist device, six for HeartMate II, three for HeartMate 3, and three for total artificial heart. Mechanisms involved in LVAD malfunction include battery malfunction, loose driveline connector, malfunction of the system controller, loose power supply connector ports, malfunction of the driveline splice kit, problems with the percutaneous lead connection, disconnection of the bend relief and outflow graft and outflow graft occlusion among others. Multiple mechanisms could be linked to LVAD malfunction. However, multiple device modifications have been developed over the past decade to avoid recurrent malfunctions. Constant improvements and research in biotechnology are needed to prevent these complications. It remains to be seen if newer generation devices will lead to improved patient outcomes over the long term.